Inventor · disambiguated record
Partha Neogi
Also filed as: NEOGI PARTHA
16 granted patents·12 pending applications·107 citations·filing 1999–2008
92Inventor score
Files withTHERACOS INC11BEXEL PHARMACEUTICALS INC9CALYX THERAPEUTICS INC3ORCHID CHEMICALS & PHARM LTD1ORCHID RES LAB LTD1
Top patents by PatentIndex Score
28 records- 0185US7521465B2Diphenyl ether derivativesBEXEL PHARMACEUTICALS INC·Filed 2005·Granted Apr 21, 2009·14 cites·24 claims
- 0284US7087576B2Dipeptide phenyl ethersBEXEL PHARMACEUTICALS INC·Filed 2003·Granted Aug 8, 2006·12 cites·23 claims
- 0379US7781464B2Heterocyclic diphenyl ethersBEXEL PHARMACEUTICALS INC·Filed 2006·Granted Aug 24, 2010·7 cites·11 claims
- 0477US7105552B2Heterocyclic analogs of diphenylethylene compoundsTHERACOS INC·Filed 2001·Granted Sep 12, 2006·10 cites·108 claims
- 0576US7521466B2Dipeptide phenyl ethersBEXEL PHARMACEUTICALS INC·Filed 2006·Granted Apr 21, 2009·2 cites·17 claims
- 0675US7399786B2Derivatives of amino acids for treatment of obesity and related disordersBEXEL PHARMACEUTICALS INC·Filed 2005·Granted Jul 15, 2008·5 cites·24 claims
- 0774US7456292B2Hydroxamic acid-containing amino acid derivativesBEXEL PHARMACEUTICALS INC·Filed 2005·Granted Nov 25, 2008·4 cites·16 claims
- 0873US6331633B1Heterocyclic analogs of diphenylethylene compoundsCALYX THERAPEUTICS INC·Filed 1999·Granted Dec 18, 2001·35 cites·8 claims
- 0972US6855732B2Compounds to treat diabetes and associated conditionsTHERACOS INC·Filed 2002·Granted Feb 15, 2005·6 cites·6 claims
- 1065US7202366B2Heterocyclic analogs of diphenylethylene compoundsTHERACOS INC·Filed 2004·Granted Apr 10, 2007·2 cites·12 claims
- 1159US7407978B2Heterocyclic analogs of diphenylethylene compoundsTHERACOS INC·Filed 2002·Granted Aug 5, 2008·1 cites·6 claims
- 1257US7718682B2Heterocyclic analogs of diphenylethylene compoundsTHERACOS INC·Filed 2008·Granted May 18, 2010·0 cites·32 claims
- 1357US6413504B1Alpha-arylated cinnamic esters and 1,4-bis(alpha-carboxyl-beta-styryl)benzene esters an UV-blocking agentsCALYX THERAPEUTICS INC·Filed 2000·Granted Jul 2, 2002·2 cites·14 claims
- 1454US7323496B2Compounds for treatment of inflammation, diabetes and related disordersTHERACOS INC·Filed 2003·Granted Jan 29, 2008·1 cites·17 claims
- 1553US2006235062A1Novel heterocyclic analogs of diphenylethylene compoundsTHERACOS INC·Filed 2003·Application pending·0 cites
- 1650US2008261981A1Novel derivatives of amino acids for treatment of obesity and related disordersBEXEL PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 1747US2008188654A1Compounds for treatment of inflammation, diabetes and related disordersTHERACOS INC·Filed 2007·Application pending·0 cites
- 1846US6525093B1Compounds to treat diabetes and associated conditionsCALYX THERAPEUTICS INC·Filed 1999·Granted Feb 25, 2003·6 cites·56 claims
- 1943US2004259938A1Novel dipheylenthylene compoundsFiled 2003·Application pending·0 cites
- 2043US2008200521A1Novel hydroxamic acid containing amino acid derivativesBEXEL PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 2142US2009069313A1Novel MAO-A inhibitorsORCHID RES LAB LTD·Filed 2007·Application pending·0 cites
- 2241US2008175795A1Novel derivatives of amino acids for treatment of obesity and related disordersBEXEL PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 2339US6723736B2Tricyclic compounds and uses thereofTHERACOS INC·Filed 2001·Granted Apr 20, 2004·0 cites·43 claims
- 2438US2008319031A1Novel Tyrosine DerivativesORCHID CHEMICALS & PHARM LTD·Filed 2006·Application pending·0 cites
- 2537US2008108825A1Compounds for treatment of inflammation, diabetes and related disordersTHERACOS INC·Filed 2007·Application pending·0 cites
- 2637US2002025975A1Novel Heterocyclic analogs of diphenylethylene compoundsFiled 2001·Application pending·0 cites
- 2737US2008103302A1Compounds for treatment of inflammation, diabetes and related disordersTHERACOS INC·Filed 2007·Application pending·0 cites
- 2834US2002002200A1Novel diphenylethylene compoundsFiled 2001·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →